Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation

Atherosclerosis

Volumn 210, Issue 2, 2010, Pages 503-509

  Auer, Johann ^a,b,c   Leitner, Alexander ^b   Berent, Robert ^d   Lamm, Gudrun ^e   Lassnig, Elisabeth ^b   Krennmair, Gerald ^f  

^a General Hospital Braunau   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c General Hospital Simbach   (Germany)

^d Center for Cardiovascular Rehabilitation   (Austria)

^e Hospital of St Pölten Lilienfeld   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bare metal stent; Coronary artery disease; Drug eluting stent; Outcome; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYPHER; HEPARIN; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STENT THROMBOSIS; TREATMENT DURATION;

AGED; ANGIOGRAPHY; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RISK; STENTS; THROMBOSIS; TREATMENT OUTCOME;

EID: 77952948745     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.12.003     Document Type: Article

References (29)

1. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773-1780.
2. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323.
3. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004, 350:221-231.
4. Stone G.W., Ellis S.G., Cannon L., et al. Comparison of a polymer based paclitaxel-eluting stent with a stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005, 294:1215-1223.
5. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004, 364:583-591.
6. Bavry A.A., Kumbhani D.J., Helton T.J., Bhatt D.L. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis. J Am Coll Cardiol 2005, 45:941-946.
7. Daemen J., Ong A.T., Stefanini G.G., et al. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry. Am J Cardiol 2006, 98:895-901.
8. Urban P., Gershlick A.H., Guagliumi G., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher Registry. Circulation 2006, 113:1434-1441.
9. Moreno R., Fernandez C., Hernandez R., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005, 45:954-959.
10. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare metal stents. J Am Coll Cardiol 2006, 48:2584-2591.
11. Nordmann A.J., Briel M., Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. stents in coronary artery disease: a meta-analysis. Eur Heart J 2006, 27:2784-2814.
12. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus and paclitaxel-eluting coronary stents. N Engl J Med 2007, 356:998-1008.
13. Lagerqvist B., James S.K., Stenestrand U., Lindbäck J., Nilsson T., Wallentin L. Long-term with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007, 356:1009-1019.
14. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
15. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 2004, 109:701-705.
16. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006, 119:1056-1061.
17. Aoki J., Colombo A., Dudek D., et al. Persistent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 2005, 112:3876-3883.
18. Update to FDA statement on coronary drug-eluting stents. Available at: [accessed December 2006]. http://www.fda.gov/cdrh/news/010407.html.
19. Spaulding C., Daemen J., Boersma E., Cutlip D.E., Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare metal stents. N Engl J Med 2007, 356:989-997.
20. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007, 356:1030-1039.
21. Rao S.V., Shaw R.E., Brindis R.G., Klein L.W., Weintraub W.S., Peterson E.D. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 2006, 97:1478-1481.
22. New standard stent-thrombosis definition yields comparable event rates for DES and bare-metal stents. Available at: [accessed October 2006]. http://www.medscape.com/viewarticle/546575.
23. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
24. Jensen L.O., Maeng M., Kaltoft A., et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 2007, 50:463-470.
25. Spaulding C., Henry P., Teiger E., et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006, 355:1093-1104.
26. Laarman G.J., Suttorp M.J., Dirksen M.T., et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006, 355:1105-1113.
27. Ong A.T., Serruys P.W., Aoki J., et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) Registry. J Am Coll Cardiol 2005, 45:1135-1141.
28. Ong A.T., van Domburg R.T., Aoki J., Sonnenschein K., Lemos P.A., Serruys P.W. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry. J Am Coll Cardiol 2006, 47:1356-1360.
29. Lemos P.A., Arampatzis C.A., Saia F., et al. Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH Registry). Am J Cardiol 2004, 93:633-636.